Get startedLog in
    Picture of HUTCHMED (China) logo

    13 — HUTCHMED (China) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia

    Picture of HUTCHMED (China) logoHUTCHMED (China)
    07/01/2026 24:02
    Jan 6 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

HUTCHMED ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE III PART OF ESLIM-02 TRIAL OF SOVLEPLENIB FOR WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA IN CHINA

HUTCHMED (CHINA) LTD - PHASE III TRIAL OF SOVLEPLENIB MEETS PRIMARY ENDPOINT

Source text: ID:nGNX40BshT

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on HUTCHMED (China)

    See all news